The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay

Hansook Kim Chong; Tao Wang; Hsiao-Mei Lu; Sara Seidler; Hong Lu; Steven Keiles; Elizabeth C. Chao; A. J. Stuenkel; Xiang Li; Aaron M. Elliott

doi:10.1371/journal.pone.0097408

Loading metrics

Open Access

Peer-reviewed

Research Article

The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay

Hansook Kim Chong,

Affiliation Department of Research and Development, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Tao Wang,

Affiliation Department of Bioinformatics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Hsiao-Mei Lu,

Affiliation Department of Bioinformatics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Sara Seidler,

Affiliation Department of Research and Development, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Hong Lu,

Affiliation Department of Bioinformatics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Steven Keiles,

Affiliation Department of Clinical Genetics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Elizabeth C. Chao,

Affiliation Department of Clinical Genetics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
A. J. Stuenkel,

Affiliation Department of Clinical Genetics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Xiang Li,

Affiliation Department of Bioinformatics, Ambry Genetics, Aliso Viejo, California, United States of America
⨯
Aaron M. Elliott

* E-mail: aelliott@ambrygen.com

Affiliation Department of Research and Development, Ambry Genetics, Aliso Viejo, California, United States of America
⨯

The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay

Hansook Kim Chong,
Tao Wang,
Hsiao-Mei Lu,
Sara Seidler,
Hong Lu,
Steven Keiles,
Elizabeth C. Chao,
A. J. Stuenkel,
Xiang Li,
Aaron M. Elliott

Published: May 15, 2014
https://doi.org/10.1371/journal.pone.0097408

Reader Comments

Post a new comment on this article

Table 2 correction

Posted by aelliott on 28 Jul 2014 at 18:03 GMT

Table 2 should be titled "Validation of BRCAplus variant detection on previously characterized samples".

All variants listed in Table 2 are not deleterious

Thank you,
Ambry Genetics

No competing interests declared.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Genetic causes of cancer
Is the Subject Area "Genetic causes of cancer" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Next-generation sequencing
Is the Subject Area "Next-generation sequencing" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Mutation detection
Is the Subject Area "Mutation detection" applicable to this article?

Thanks for your feedback.
Bioinformatics
Is the Subject Area "Bioinformatics" applicable to this article?

Thanks for your feedback.
Dideoxy DNA sequencing
Is the Subject Area "Dideoxy DNA sequencing" applicable to this article?

Thanks for your feedback.
Polymerase chain reaction
Is the Subject Area "Polymerase chain reaction" applicable to this article?

Thanks for your feedback.

The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay

The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay

Reader Comments

Post Your Discussion Comment

Why should this posting be reviewed?

Thank You!

Table 2 correction

Posted by aelliott on 28 Jul 2014 at 18:03 GMT